YycG-IN-1

YycG-IN-1 (compound 16) inhibits the planktonic growth of multiple Gram-positive bacterial strains (Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecium, Streptococcus agalactiae) with MIC values of 12.5-25 μM, and exhibits no inhibitory effect on Escherichia coli ATCC 29522 even at concentrations as high as 200 μM^[1].
YycG-IN-1 (25 μM; up to 24 h), at its MIC of 25 μM, in combination with Ampicillin (HY-B0522), Vancomycin (HY-B0671), or Linezolid (HY-10394) at concentrations of 1/2 of their respective MICs, rapidly reduces the viable count of planktonic Enterococcus faecalis OG1RF by >3 log₁₀ CFUs within 3 h, and this bactericidal activity persists for more than 24 h^[1].
YycG-IN-1 inhibits the formation of mature biofilms of Enterococcus faecalis FB-1 at a concentration of 50 μM, with an inhibition rate of 63.7-85.1%; it significantly inhibits the dynamic biofilm formation of Enterococcus faecalis FB-1 in a fluid shear system at a concentration of 25 μM^[1].
YycG-IN-1 reduces the survival rate of biofilm-embedded Enterococcus faecalis cells to 18.29% at a concentration of 50 μM ^[1].
YycG-IN-1 inhibits the planktonic growth of 257 clinical Enterococcus faecalis strains (including vancomycin-resistant and linezolid-resistant strains), with MIC values of 25-100 μM and MIC₅₀/MIC₉₀ of 50/100 μM^[1].
YycG-IN-1 (1/2 × MIC; 24 h) inhibits biofilm formation of 10 strongly biofilm-positive clinical Enterococcus faecalis strains by 74.8%-97.4%^[1].

YycG-IN-1 inhibits the kinase activity of purified recombinant YycG′ protein derived from Enterococcus faecalis OG1RF with an IC₅₀ of 42.9 μM; it binds to the purified recombinant YycG′ protein from Enterococcus faecalis OG1RF with a K_D value of 86.4 μM^[1].
YycG-IN-1 (25 μM; 6 h) downregulates the expression of yycG, yycF and multiple biofilm-associated genes (epbA, epaOX, fsrB, gelE, sprE) in Enterococcus faecalis^[1].